Recent News

EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC

Brigatinib in Alectinib-Resistant ALK-Positive NSCLC

Updated USPSTF Recommendation on Lung Cancer Screening

Novel Bispecific PD-L1 and CTLA-4 Antibody for Metastatic NSCLC

Tyrosine Kinase Inhibitor Combination Therapy for HER2-Mutated NSCLC

Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC

Do Tailored Chemotherapy Regimens Improve Outcomes in Early-Stage NSCLC?

FDA Expands Approval of Lorlatinib for ALK-Positive Non–Small Cell Lung Cancer

Tyrosine Kinase Inhibitor Therapy for Stage III EGFR-Mutated NSCLC

WCLC 2020: 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC

WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC

FDA Approves Cemiplimab-rwlc and Expands Approval of Companion Diagnostic in NSCLC

WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC

Sotorasib Receives FDA Priority Review for KRAS G12C–Mutated Advanced Lung Cancer

WCLC 2020: KEYNOTE-799 Update on Pembrolizumab With Chemoradiotherapy in Stage III Lung Cancer

WCLC 2020: Updated Overall Survival With Atezolizumab in NSCLC From IMpower110

WCLC 2020: Patient-Reported Outcomes With Lorlatinib Versus Crizotinib in ALK-Positive NSCLC

WCLC 2020: Genomic Analysis of Women With Lung Cancer Who Never Smoked

WCLC 2020: Adding Ipilimumab to Pembrolizumab for Metastatic NSCLC

Tepotinib Granted Accelerated Approval by FDA in Metastatic NSCLC

WCLC 2020: Small-Molecule Inhibitor Active in KRAS G12C–Mutated NSCLC

WCLC 2020: Novel Tyrosine Kinase Inhibitor Versus Chemotherapy for EGFR-Mutated NSCLC

Outcomes With Durvalumab After Chemoradiotherapy for NSCLC

JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC

FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers

Biomarker May Predict Susceptibility to Radiation Pneumonitis in Patients With Lung Cancer

Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC

Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?

Lorlatinib Receives Priority Review in Untreated ALK-Positive Lung Cancer

Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer

Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC

Stereotactic Body Radiotherapy for Larger Lung Tumors

First-Line Pembrolizumab Plus Niraparib in Advanced Metastatic NSCLC

Ramucirumab Plus Osimertinib in NSCLC: Final Analysis of Phase I Trial

Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC

Targeting KRAS Mutations in Advanced NSCLC: Early Trial Results

Capmatinib in MET-Dysregulated Advanced NSCLC: GEOMETRY Mono-1

ESMO Asia 2020: Adding PD-L1 Inhibitor to Platinum-Based Chemotherapy for NSCLC

Lorlatinib for First-Line Treatment of ALK-Positive NSCLC

SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma

SITC 2020: Vactosertib Plus Durvalumab in PD-L1–Positive NSCLC

ASTRO 2020: Pericardial Effusion and Survival With Radiation Therapies in Locally Advanced NSCLC

Timing of Brain Radiotherapy for NSCLC With Brain Metastasis

ASTRO 2020: Stereotactic Body Radiotherapy With and Without Pembrolizumab Under Study in Lung Cancer

Equivalence Study of Bevacizumab Biosimilar in Metastatic Nonsquamous NSCLC

ASTRO 2020: Cardiac Events With Photon Versus Proton Radiotherapy for Lung Cancer

Lung Cancer and Severity of COVID-19: Experience From MSK

Osimertinib Receives Priority Review for EGFR-Mutant NSCLC

Early Clinical Data on Sotorasib in Advanced NSCLC

Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153